Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02365818 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure
A Phase 2 study, sponsored by CG Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT02365818 is a Phase 2 study that has completed, run by CG Oncology. The registered enrollment target is 66 participants.
The verdict
NCT02365818, a Phase 2 study, has completed, sponsored by CG Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
To study the safety and efficacy of CG0070, an oncolytic virus expression GM-CSF in high grade non muscle invasive bladder cancer patients who failed BCG therapy and refused cystectomy.
Interventions
- BIOLOGICAL CG0070
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2015-06-02 |
| Est. Completion | 2019-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02365818
The ClinicalTrials.gov registry entry for NCT02365818 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CG Oncology, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CG0070 is the first listed.
NCT02365818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02365818 about?
NCT02365818 is a clinical study titled "Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure". To study the safety and efficacy of CG0070, an oncolytic virus expression GM-CSF in high grade non muscle invasive bladder cancer patients who failed BCG therapy and refused cystectomy.
What is the current status of trial NCT02365818?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2015-06-02. Estimated completion is 2019-02.
What interventions are being tested in trial NCT02365818?
The interventions under investigation include: CG0070 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02365818?
This trial is sponsored by CG Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.